Citius Pharmaceuticals (CTXR) Operating Expenses (2010 - 2026)

Citius Pharmaceuticals (CTXR) has reported Operating Expenses for 17 consecutive years, with $12.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 44.9% year-over-year to $12.7 million; the trailing twelve-month figure through Jun 2026 stood at $66.9 million (up 62.57% YoY), and the FY2025 full-year result was $38.5 million, down 8.26% from the prior year.
• Operating Expenses fell to $12.7 million in Q2 2026 per CTXR's latest filing, from $33.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $33.5 million in Q1 2026 and bottomed at $7.2 million in Q4 2022.
• Historically, Operating Expenses has averaged $11.1 million across 5 years, with a median of $10.1 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses slipped 23.65% in 2025, then soared 197.79% in 2026.
• Over 5 years, Operating Expenses stood at $7.2 million in 2022, then grew by 28.84% to $9.3 million in 2023, then gained by 7.48% to $10.0 million in 2024, then gained by 21.26% to $12.2 million in 2025, then rose by 4.6% to $12.7 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $12.7 million, $33.5 million, and $12.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.